ReviewCurrent oncology (Toronto, Ont.)2024
Review on Lymph Node Metastases, Sentinel Lymph Node Biopsy, and Lymphadenectomy in Sarcoma.
Review in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- [When and how are pulmonary metastases surgically treated in sarcomas?]Chirurgie (Heidelberg, Germany) · 2026Review
- Epithelioid Sarcoma: A Review and Update.Cancers · 2026Review
- Proposal of a Risk Stratification Algorithm for Extracranial Malignant Rhabdoid Tumors.Cancer medicine · 2026Article
- Primary lymphatic leiomyosarcoma presenting as a pelvic mass.Gynecologic oncology reports · 2026Article
- Case Report: The deceptive vein - when benign-appearing laryngeal lesions mask primary laryngeal classic Kaposi sarcoma.Frontiers in oncology · 2026Article
- Microsatellite instability and PD-L1 expression in sarcomas: current evidence and clinical perspectives.Medical oncology (Northwood, London, England) · 2025Review
- Development of a carbon nanoparticle-guided nomogram for predicting lateral cervical lymph node metastasis in clinically node-negative papillary thyroid carcinoma.American journal of translational research · 2025Article
- Clinical Value of Vascular Cancer Thrombus and Myometrial Invasion Combined with Tumor Markers in Predicting Sentinel Lymph Node Metastasis of Endometrial Cancer.Cancer management and research · 2025Article
- Characterization of intrinsic subtypes of breast cancer and their relationship with staging: an observational study.Frontiers in medicine · 2025Article
- Quantitative and qualitative analysis of contrast-enhanced ultrasound for differentiating benign and malignant superficial enlarged lymph nodes.Quantitative imaging in medicine and surgery · 2024Article
- The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor's biology and their translational prospects.Molecular cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Soft tissue sarcomas (STS) originating from connective tissue rarely affect the lymph nodes. However, involvement of lymph nodes in STS is an important aspect of prognosis and treatment. Currently, there is no consensus on the diagnosis and management of lymph node metastases in STS. The key risk factor for nodal involvement is the histological subtype of sarcoma. Radiological and pathological evaluation seems to be the most effective method of assessing lymph nodes in these neoplasms. Thus, sentinel lymph node biopsy (SLNB), which has been shown to be valuable in the management of melanoma or breast cancer, may also be a beneficial diagnostic option in some high-risk STS subtypes. This review summarizes data on the risk factors and clinical characteristics of lymph node involvement in STS. Possible management and therapeutic options are also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.